Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators.

Esteban Rodríguez-MartinóRafael Medina-PrietoJorge Santana-BagurMaría SantéPetraleigh PantojaAna M EspinoCarlos A A SariolEsther A Torres

Published in: medRxiv : the preprint server for health sciences (2021)

Neutralizing capacity response to the vaccine in subjects was similar to a healthy cohort in spite of lower increases in total IgG antibodies. The CD4 and CD8 results observed may support the capacity to mount an effective cellular response in patients on biologics. Larger studies are needed to determine vaccine efficacy in these patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
coronavirus disease
peritoneal dialysis
patient reported outcomes
zika virus
binding protein
dengue virus